Physician profile
Michael Dash
NPI 1982023214
$1,974.88
in general payments reported to CMS, 2019-2025
21 companies · $86.92 in 2025
The $86.92 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $125 · 2021: $276 · 2022: $257 · 2023: $458 · 2024: $368 · 2025: $86.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $215.01 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $213.06 | 2022-2024 | Alden Scleral Zenlens, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $206.32 | 2019-2024 | Cequa |
| Dompe US, INC. | $193.17 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $179.66 | 2019-2022 | |
| Alcon Vision LLC | $151.26 | 2019-2024 | Rocklatan |
| Horizon Therapeutics Plc | $140.00 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $134.04 | 2021-2022 | |
| Glaukos Corporation | $71.70 | 2021-2024 | Photrexa |
| Quidel Corporation | $66.74 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.37 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $57.26 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $56.77 | 2019 | |
| Abbvie INC. | $50.39 | 2023-2025 | Durysta |
| Johnson & Johnson Surgical Vision, INC. | $33.34 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $32.54 | 2019 | |
| Amgen INC. | $30.05 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $21.97 | 2022 | |
| Mallinckrodt Enterprises LLC | $21.40 | 2019 | |
| Aerie Pharmaceuticals, INC. | $18.95 | 2021 | |
| Optos, INC. | $15.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.